Methotrexate

• CAT Number: I000021
• CAS Number: 59-05-2
• Molecular Formula: C20H22N8O5
• Molecular Weight: 454.4
• Purity: ≥95%
• Target: DHFR
• Solubility: 10 mM in DMSO
• Storage: 3 years -20C powder
• InChI: InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
• InChIKey: FBOZXECLQNJBKD-ZDUSSCGKSA-N
• SMILES: NC1=NC(N)=C2C(N=CC(CN(C3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)C=C3)C)=N2)=N1

Methotrexate (CAT: I000021) is a medication used in the treatment of various cancers, including leukemia, lymphoma, and solid tumors. It belongs to the class of drugs known as antimetabolites, which inhibit the synthesis of DNA and RNA in rapidly dividing cells. Methotrexate is also used to treat certain autoimmune diseases such as rheumatoid arthritis and psoriasis. It works by suppressing the immune system and reducing inflammation. Methotrexate is usually taken orally or administered via injection. Common side effects may include nausea, fatigue, and decreased blood cell counts. Regular monitoring of liver function and blood cell counts is necessary during treatment.

Reference

1:Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Liu SG, Gao C, Zhang RD, Zhao XX, Cui L, Li WJ, Chen ZP, Yue ZX, Zhang YY, Wu MY, Wang JX, Li ZG, Zheng HY.Oncotarget. 2017 May 10. doi: 10.18632/oncotarget.17781. [Epub ahead of print] PMID: 28525903
2:Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece. Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N.Rheumatol Int. 2017 May 18. doi: 10.1007/s00296-017-3736-z. [Epub ahead of print] PMID: 28523420
3:Methotrexate encephalopathy: Two cases in adult cancer patients, who recovered with pathophysiologically based therapy. Coker SA, Pastel DA, Davis MC, Bengtson EM, Fadul CE, Lewis LD.SAGE Open Med Case Rep. 2017 May 4;5:2050313X17706875. doi: 10.1177/2050313X17706875. eCollection 2017. PMID: 28515935
4:HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment. West J, Ogston S, Berg J, Palmer C, Fleming C, Kumar V, Foerster J.Clin Exp Dermatol. 2017 May 17. doi: 10.1111/ced.13100. [Epub ahead of print] PMID: 28512993
5:Histopathological Features of Methotrexate Induced Pulmonary Lesions in Rheumatoid Arthritis Patients: A Systematic Review of Case Reports. Thaniyan A, Ayman FFA, Mirghani HO, Al-Sayed BA, Merghani TH.Open Access Maced J Med Sci. 2017 Apr 8;5(2):266-270. doi: 10.3889/oamjms.2017.049. eCollection 2017 Apr 15. Review. PMID: 28507640 Free PMC Article
6:Methotrexate: an effective monotherapy for refractory generalized morphea. Platsidaki E, Tzanetakou V, Kouris A, Stavropoulos PG.Clin Cosmet Investig Dermatol. 2017 May 8;10:165-169. doi: 10.2147/CCID.S134879. eCollection 2017. PMID: 28507446 Free PMC Article
7:Quantitative on-line liquid chromatography-surface- enhanced Raman scattering (LC-SERS) of methotrexate and its major metabolites. Subaihi A, Trivedi DK, Hollywood KA, Bluett J, Xu Y, Muhamadali H, Ellis DI, Goodacre R.Anal Chem. 2017 May 15. doi: 10.1021/acs.analchem.7b00916. [Epub ahead of print] PMID: 28505414
8:Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies. Ikeda K, Watanabe K, Hirai T, Tanji K, Miyashita T, Nakajima S, Uomori K, Morimoto S, Takamori K, Ogawa H, Takasaki Y, Sekigawa I.Intern Med. 2017;56(10):1147-1152. doi: 10.2169/internalmedicine.56.7886. Epub 2017 May 15. PMID: 28502927 Free Article
9:Nausea and vomiting in children and adolescents receiving intrathecal methotrexate: A prospective, observational study. Flank J, Nadeem K, Moledina S, Khanna M, Schindera C, Punnett A, Dupuis LL.Pediatr Blood Cancer. 2017 May 13. doi: 10.1002/pbc.26603. [Epub ahead of print] PMID: 28500750
10:Response to: /'HLA-A* 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome wide association study/’ by Bluett et al. Furukawa H, Oka S, Shimada K, Tsuchiya N, Tohma S; Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) Study Consortium..Ann Rheum Dis. 2017 May 12. pii: annrheumdis-2017-211518. doi: 10.1136/annrheumdis-2017-211518. [Epub ahead of print] No abstract available. PMID: 28500058